Flucytosine

Generic Name: Flucytosine

Brand Names: Ancobon

Drug Type: Small Molecule

Chemical Formula: C_₄H_₄FN_₃O

CAS Number: 2022-85-7

Unique Ingredient Identifier: D83282DT06

Background: A fluorinated cytosine analog that is used as an antifungal agent.

Indication: For the treatment (in combination with amphotericin B) of serious infections caused by susceptible strains of Candida (septicemia, endocarditis and urinary system infections) and/or Cryptococcus (meningitis and pulmonary infections).

Associated Conditions: Candidiasis, Candidiasis, Systemic, Cryptococcal infections, Fungal Infections, Fungal endocarditis, Meningitis, Fungal, Septicemia, Urinary tract infection fungal, Disseminated Cryptococcosis

Associated Therapies: -

Clinical Trials

Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis

Phase 2

Completed

Conditions: Cryptococcal Meningitis

Interventions: Drug: AMBITION trial control
Drug: Flucytosine

First Posted Date: 2024-05-16

Last Posted Date: 2024-10-03

Lead Sponsor: University of Minnesota

Target Recruit Count: 47

Registration Number: NCT06414512

Locations: 🇺🇬
Infectious Disease Institute, Mulago Hospital Complex, Kampala, Uganda
🇺🇬
Mbarara University of Science and Technology, Mbarara, Uganda

Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis

Not Applicable

Conditions: Cryptococcal Meningitis

Interventions: Drug: Amphotericin B Colloidal Dispersion
Drug: flucytosine
Drug: fluconazole

First Posted Date: 2022-07-22

Last Posted Date: 2022-07-22

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 30

Registration Number: NCT05471063

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

AmB Dose for Cryptococcal Meningitis

Phase 3

Conditions: Cryptococcal Meningitis
HIV Infections

Interventions: Drug: Amphotericin B
Drug: Flucytosine

First Posted Date: 2019-10-25

Last Posted Date: 2019-10-29

Lead Sponsor: Shanghai Public Health Clinical Center

Target Recruit Count: 40

Registration Number: NCT04140461

Locations: 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China

Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas

Phase 1

Completed

Conditions: Adult Glioblastoma
Adult Anaplastic Astrocytoma
Adult Giant Cell Glioblastoma
Anaplastic Oligoastrocytoma
Recurrent Adult Brain Tumor
Adult Anaplastic Oligodendroglioma
Adult Gliosarcoma

Interventions: Biological: E. coli CD-expressing genetically modified neural stem cells
Drug: flucytosine
Drug: leucovorin calcium
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2013-12-19

Last Posted Date: 2021-10-20

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 16

Registration Number: NCT02015819

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa

Phase 2

Conditions: Cryptococcal Meningitis
HIV

Interventions: Drug: Fluconazole
Drug: Flucytosine
Procedure: lumbar punctures

First Posted Date: 2012-10-29

Last Posted Date: 2016-07-12

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 41

Registration Number: NCT01715922

Locations: 🇧🇮
Hôpital général, Muyinga, Burundi
🇨🇮
Service de Maladies Infectieuses & Tropicales - Hôpital Triechville, Abidjan, Côte D'Ivoire
🇧🇮
CHU Kamenge, Bujumbura, Burundi

and more 2 locations

A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas

Phase 1

Completed

Conditions: Adult Anaplastic Astrocytoma
Adult Gliosarcoma
Adult Mixed Glioma
Recurrent Grade III Glioma
Adult Giant Cell Glioblastoma
Recurrent High Grade Glioma
Recurrent Grade IV Glioma
Adult Anaplastic Oligodendroglioma
Adult Brain Tumor
Adult Glioblastoma

Interventions: Drug: flucytosine
Other: polymerase chain reaction
Other: immunohistochemistry staining method
Biological: gene therapy
Other: pharmacological study
Other: 3-Tesla magnetic resonance imaging
Other: laboratory biomarker analysis
Procedure: therapeutic conventional surgery
Biological: E. coli CD-expressing genetically modified neural stem cells

First Posted Date: 2010-07-30

Last Posted Date: 2017-11-09

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 15

Registration Number: NCT01172964

Locations: 🇺🇸
City of Hope, Duarte, California, United States

A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis

Not Applicable

Completed

Conditions: Meningitis, Cryptococcal
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 400

Registration Number: NCT00000639

Locations: 🇺🇸
Ucsf Aids Crs, San Francisco, California, United States
🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸
Northwestern University CRS, Chicago, Illinois, United States

and more 21 locations

A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.

Not Applicable

Completed

Conditions: Meningitis, Cryptococcal
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Pfizer

Target Recruit Count: 64

Registration Number: NCT00002113

Locations: 🇺🇸
UCSD Med Ctr - Owen Clinic, San Diego, California, United States
🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸
UCI Med Ctr, Orange, California, United States

Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

Not Applicable

Completed

Conditions: Meningitis, Cryptococcal
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Pfizer

Registration Number: NCT00002075

Locations: 🇺🇸
Dr Robert Larsen, Los Angeles, California, United States

A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis

Not Applicable

Completed

Conditions: Meningitis, Cryptococcal
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Pfizer

Registration Number: NCT00002305

Locations: 🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸
Emory Univ School of Medicine, Atlanta, Georgia, United States
🇺🇸
DeKalb Gen Hosp, Decatur, Georgia, United States

and more 42 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy